InvestorsHub Logo
Followers 58
Posts 10159
Boards Moderated 1
Alias Born 09/21/2016

Re: None

Tuesday, 01/03/2023 10:05:06 AM

Tuesday, January 03, 2023 10:05:06 AM

Post# of 462745
The biggest science issue here on AD has been the confidence levels assigned or assumed on what and HOW to measure AD treatment efficacy. IMO. FDA and BP have been stabbing in the dark for decades to demonstrate the causal links to Amyloid plaques . AVXL have gone on a different path and, we look to be close to be recognized as the winner. Bottom line (IMO) is ,will FDA FINALLY admit their Amyloid HORSE HAS DIED?

Dr.M. and the AVXL team are about to be recognized as winning rounding the clubhouse turn...heading to the finish line (BTW) we got RSD AND others along w/AD. Everybody WINS.

The GOOD NEWS IS...(IMO) now, AD and other CNS disease will be properly assessed (eventually). AND,, the FDA will FINALLY be redirected to research and spend on AD-CNS things that matter. That will be traumatic.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News